Pharmacoeconomics

Published on 02/03/2015 by admin

Filed under Basic Science

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1377 times

8 Pharmacoeconomics

The demand for and the cost of health care are growing in all countries. Many governments are focusing their activities on promoting the effective and economic use of resources allocated to health care. The increased use of evidence-based programmes not only concentrates on optimizing health outcomes but also utilises health economic evaluations.

While there have been marked gains in life expectancy in those countries which make up the Organization for Economic Co-operation and Development (OECD), health costs have also risen in all of them. The USA spent 16% of its national income (gross domestic product, GDP) on health in 2007, a value considerably greater than many other OECD countries (Fig. 8.1).

Medicines form a small but significant proportion of total health care costs; this has been increasing consistently as new medicines are marketed. For example, the overall NHS expenditure on medicines in England in 2008 was £11.6 billion. Primary care expenditure was £8.1 million and hospital use accounted for 28.7% of the total cost at £3.3 million, up from 25.8% in 2007. The cost of medicines has increased by 3.4% overall and by 15.2% in hospitals.

Most OECD countries have seen growth in spending on medicines outstrip growth in total health spending over this period. In the USA and Australia, pharmaceutical spending has increased at more than double the rate of growth in total health spending (OECD, 2009).

There are a number of reasons why prescribing costs are increasing:

In the UK, health reforms over the past decade have addressed the quality of care through promotion of quality and safety standards. The formation of NICE in 1998 ‘to improve standards of patient care and to reduce inequities in access to innovative treatment’ has formalised this process. NICE undertakes appraisals of medicines and other treatments (health technologies) and addresses the clinical and cost-effectiveness of therapies and compares outcomes with alternative use of NHS funds. The increased use of evidence-based programmes not only concentrates on optimizing health outcomes but also utilises health economic evaluations. Formalised health technology assessments provide an in-depth and evidence-based approach to this process.

Terms used in health economics

Pharmacoeconomics can be defined as the measurement of both the costs and consequences of therapeutic decision making. Pharmacoeconomics provides a guide for decision makers on resource allocation but does not offer a basis on which decisions should be made. Pharmacoeconomics can assist in the planning process and help assign priorities where, for example, medicines with a worse outcome may be available at a lower cost and medicines with better outcome and higher cost can be compared.

When economic evaluations are conducted it is important to categorise various costs. Costs can be direct to the organisation, that is physicians’ salaries, the acquisition costs of medicines, consumables associated with drug administration, staff time in preparation and administration of medicines, laboratory charges for monitoring effectiveness and adverse drug reactions. Indirect costs include lost productivity from a disease which can manifest itself as a cost to the economy or taxation system as well as economic costs to the patient and the patient’s family. All aspects of the use of medicines may be allocated costs, both direct, such as acquisition and administration costs, and indirect, such as the cost of a given patient’s time off work because of illness, in terms of lost output and social security payments. The consequences of drug therapy include benefits for both the individual patient and society at large and may be quantified in terms of health outcome and quality of life, in addition to the purely economic impact.

It is worthwhile here to describe a number of definitions that further qualify costs in a health care setting. The concept of opportunity cost is at the centre of economics and identifies the value of opportunities which have been lost by utilizing resources in a particular service or health technology. This can be valued as the benefits that have been forsaken by investing the resources in the best alternative fashion. Opportunity cost recognises that there are limited resources available for utilising every treatment, and therefore the rationing of health care is implicit in such a system.

Average costs are the simplest way of valuing the consumption of health care resources. Quite simply, they represent the total costs (i.e. all the costs incurred in the delivery of a service) of a health care system divided by the units of production. For example, a hospital might treat 75,000 patients a year (defined as finished consultant episodes, FCEs) and have a total annual revenue cost of £150 million. The average cost per FCE is, therefore, £2000.

Fixed costs are those which are independent of the number of units of production and include heating, lighting and fixed staffing costs. Variable costs, on the other hand, are dependent on the numbers of units of productivity. The cost of the consumption of medicines is a good example of variable costs.

The inevitable increases in the medicines budget in a particular institute which is treating more patients, or treating those with a more complex pathology, have often been erroneously interpreted by financial managers as a failure to effectively manage the budget. To better describe the costs associated with a health care intervention, economists employ the term ‘marginal costs’ to describe the costs of producing an extra unit of a particular service. The term ‘incremental cost’ is employed to define the difference between the costs of alternative interventions.

Types of health economic evaluations

Cost–benefit analysis (CBA)

In CBA, consequences are measured in terms of the total cost associated with a programme where both costs and consequences are measured in monetary terms. While this type of analysis is preferred by economists, its use in health care is problematical as it is frequently difficult to ascribe monetary values to clinical outcomes such as pain relief, avoidance of stroke or improvements in quality of life.

Methods are available for determining cost–benefit for individual groups of patients that centre around a concept known as contingent valuation. Specific techniques include willingness to pay, where patients are asked to state how much they would be prepared to pay to avoid a particular event or symptom, for example pain or nausea following day-care surgery. Willingness to pay can be fraught with difficulties of interpretation in countries with socialised health care systems which are invariably funded out of general taxation. Willingness to accept is a similar concept but is based on the minimum amount an individual person or population would receive in order to be prepared to lose or reduce a service.

CBA can be usefully employed at a macro level for strategic decisions on health care programmes. For example, a countrywide immunisation programme can be fully costed in terms of resource utilisation consumed in running the programme. This can then be valued against the reduced mortality and morbidity that occur as a result of the programme.

CBA can be useful in examining the value of services, for example centralised intravenous additive services where a comparison between a pharmacy-based intravenous additive service and ward-based preparation by doctors and nurses may demonstrate the value of the centralised pharmacy service, or a clinical pharmacokinetics service where the staffing and equipment costs can be offset against the benefits of reduced morbidity and mortality.

Cost-effectiveness analysis (CEA)

CEA can be described as an examination of the costs of two or more programmes which have the same clinical outcome as measured in physical units, for example lives saved or reduced morbidity. Treatments with dissimilar outcomes can also be analysed by this technique. Where two or more interventions have been shown to be or are assumed to be similar, then if all other factors are equal, for example convenience, side effects, availability, etc., selection can be made on the basis of cost. This type of analysis is called cost-minimisation analysis (CMA). CMA is frequently employed in formulary decision making where often the available evidence for a new product appears to be no better than for existing products. This is invariably what happens in practice as clinical trials on new medicines are statistically powered for equivalence as a requirement for licensing submission.

As previously described, CEA examines the costs associated with achieving a defined health outcome. While these outcomes can be relief of symptoms such as nausea and vomiting avoided, pain relieved, etc., CEA frequently employs years of life gained as a measure of the success of a particular programme. This can then offer a method of incrementally comparing the costs associated with two or more interventions. For example, consider a hypothetical case of the comparison of two drug treatments for the management of malignant disease.

Treatment 1 represents a 1-year course of treatment for a particular malignant disease. Assume that this is the current standard form of treatment and that the average total direct costs associated with this programme are £A per year. This will include the costs of the medicines, antiemetics, inpatient stay, radiology and pathology. Treatment 2 is a new drug treatment for the malignancy which as a result of comparative controlled clinical trials has demonstrated an improvement in the average life expectancy for this group of patients from 3.5 years for treatment 1 to 4.5 years for treatment 2. The average annual total costs for treatment 2 are £B. A comparative table can now be constructed.

Strategy Treatment costs Effectiveness
Treatment 1 £A 3.5 years
Treatment 2 £B 4.5 years

Incremental cost-effectiveness ratio:

image

Cost–utility analysis (CUA)

An alternative measurement for the consequences of a health care intervention is the concept of utility. Utility provides a method for estimating patient preference for a particular intervention in terms of the patient’s state of well-being. Utility is described by an index which ranges between 0 (representing death) and 1 (perfect health). The product of utility and life years gained provides the term quality-adjusted life-year (QALY).

There are a number of methods for the calculation of utilities.

Using the previous model, if treatment 1 provides on average an increase of 3.5 years life expectancy but that this is valued at a utility of 0.9, then the health gain for this intervention is 0.9 × 3.5 = 3.15 QALYs. Similarly, if the increase in life expectancy with treatment 2 only has a utility of 0.8 (perhaps because it produces more nausea) then the health gain for this option becomes 0.8 × 4.5 = 3.6 QALYS. An incremental CUA can be undertaken as follows:

image

Incremental cost–utility ratio:

image

The calculation of QALYs provides a method which enables decision makers to compare different health interventions and assign priorities for decisions on resource allocation. However, the use of QALY league tables has provided much debate amongst stakeholders of health care as to their value and use.

According to NICE, there is no empirical basis for assigning a particular value (or values) to the cut-off between cost-effectiveness and cost-ineffectiveness. The general view is that those interventions with an incremental cost-effectiveness ratio of less than £20,000 per QALY should be supported and that there should be increasingly strong reasons for accepting as cost-effective interventions with an incremental cost-effectiveness ratio of over £30,000 per QALY.

Costs and consequences

Decision analysis

Decision analysis offers a method of pictorial representation of treatment decisions. If the results from clinical trials are available, probabilities can be placed within the arms of a decision tree and outcomes can be assessed in either monetary or quality units. An example of this can be found in the assessment of glycoprotein IIb/IIIa inhibitors in acute coronary syndrome (National Institute for Health and Clinical Excellence, 2002). The evidence of clinical and economic outcomes compares percutaneous coronary intervention and coronary artery bypass grafting. To populate a decision tree, it is necessary to obtain information from the literature on the probabilities for the clinical benefits and risks of each procedure (Table 8.1). The costs of the various procedures, consumables and bed stay are then calculated (Table 8.2). From these a decision tree can be constructed that determines the cost-effectiveness of one intervention over another (Fig. 8.2).

Table 8.1 Baseline probabilities used in the short-term model of percutaneous coronary intervention (PCI) versus coronary artery bypass graph (CABG; National Institute for Health and Clinical Excellence, 2002)

image

image

Table 8.2 Unit costs used in the analysis of percutaneous coronary intervention (PCI) versus coronary artery bypass graph (CABG; National Institute for Health and Clinical Excellence, 2002)

Unit cost Unit Base-case value
PCI Procedure £1410.04
CABG Procedure £4902.22
Repeat PCI Per diem £2976
Angiogram Procedure £748.25
Cardiac ward Day £157.47
Non-cardiac ward Day £244.00
CCU Day £459.04
Outpatient Visit £59.70
Cardiac day case Visit £108.58
Non-cardiac day case Visit £182.00
Guidewire Item £61.75
Stent Item £599.01
Guiding catheter Item £37.05
Blood Unit £85.00
Full blood count Item £4.00
Endoscopy Item £246.00
Tirofiban 12.5 mg vial £146.11 (+VAT)
Eptifibatide 20 mg vial £15.54 (+VAT)
Eptifibatide 75 mg vial £48.84 (+VAT)
Unit cost Unit Base-case value
Abciximab 10 mg vial £280.00 (+VAT)
Omeprazole 28 tab pack 10 mg £18.91
Clopidogrel 28 tab pack 75 mg £35.31

CABG, coronary artery bypass graft; CCU, coronary care unit; PCI, percutaneous coronary intervention.

If there is uncertainty about the robustness of the values of the variables within the tree, they can be varied within defined ranges to see if the overall direction of the tree changes. This is referred to as sensitivity analysis and is one of the most powerful tools available in an economic evaluation.

Conclusion

A fundamental element of the use of pharmacoeconomics in practice is the viewpoint from which the analysis is conducted. Ideally this should be from a societal perspective but frequently it is from a government or Department of Health viewpoint. Purchasers of health care may also have a different perspective from provider units, and the viewpoint of clinicians may differ from that of the patient. The pharmaceutical industry will probably have another viewpoint that will be focused on their particular products. As a consequence, with all economic evaluations the perspective from which they have been analysed should be clear.

The effect of having budgets that are rigorously defended in every section of the health service, as occurs with the medicines budget, is to deny the application of economic decision making in the most efficient way for the population served. It is clear that pharmacoeconomics has an important part to play in the practice of therapeutics (Box 8.1) and needs to be an integral part of all planned therapeutic developments.

References

Department of Health. Pharmacy in England, Building on Strengths – Delivering the Future. London: DH. 2008:1-141.

Department of Health. Using the Commissioning for Quality and Innovation (CQUIN) Payment Framework – An Addendum to the 2008 Policy Guidance for 2010/11. London: Department of Health; 2010.

Department of Health and Health Protection Agency. Clostridium difficile: How to Deal with the Problem. London: DH; 2008.

Drummond M.F, Sculpher M.J, Torrance G.W, et al, editors. Methods for the Economic Evaluation of Health Care Programmes, third ed., Oxford: Oxford University Press, 2005.

Horne R., Weinman J., Barber N., et al. Concordance, Adherence and Compliance in Medicine-Taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D; 2005.

National Institute for Health and Clinical Excellence. Guidance on the Use of Glycoprotein IIb/IIIa Inhibitors in the Treatment of Acute Coronary Syndromes. London: NICE; 2002. Available at: http://guidance.nice.org.uk/TA47/Guidance/pdf/English

National Institute for Health and Clinical Excellence. The Guidelines Manual 2009. London: NICE. 2009:81-91. Available at: http://www.nice.org.uk/media/68D/29/The_guidelines_manual_2009_Chapter_7_Assessing_cost_effectiveness.pdf

National Institute for Health and Clinical Excellence. Medicines Adherence: Involving Patients in Decisions About Prescribed Medicines CG 76. London: NICE; 2009. Available at: http://guidance.nice.org.uk/CG76/Guidance/pdf/English

OECD. Health Data. Available at: http://www.ecosante.org/index2.php?base=OCDE&langh=ENG&langs=ENG&sessionid=, 2009.